AI may predict Alzheimer's five years in advance

Image
Press Trust of India Toronto
Last Updated : Oct 08 2018 | 11:15 AM IST

Scientists -- including one of Indian origin -- have created an artificial intelligence (AI) algorithm that can accurately predict whether a person's cognitive decline will lead to Alzheimer's disease in the next five years.

Researchers from the University of Toronto in Canada designed an algorithm that learns signatures from magnetic resonance imaging (MRI), genetics, and clinical data.

According to the study published in PLOS Computational Biology, the algorithm can help predict whether an individual's cognitive faculties are likely to deteriorate towards Alzheimer's in the next five years.

"At the moment, there are limited ways to treat Alzheimer's and the best evidence we have is for prevention. Our AI methodology could have significant implications as a 'doctor's assistant' that would help stream people onto the right pathway for treatment," said Mallar Chakravarty, an assistant professor in McGill University in Canada.

For example, one could even initiate lifestyle changes that may delay the beginning stages of Alzheimer's or even prevent it altogether," said Chakravarty.

The researchers trained their algorithms using data from more than 800 people ranging from normal healthy seniors to those experiencing mild cognitive impairment, and Alzheimer's disease patients.

"We are currently working on testing the accuracy of predictions using new data. It will help us to refine predictions and determine if we can predict even farther into the future," said Chakravarty.

With more data, the scientists would be able to better identify those in the population at greatest risk for cognitive decline leading to Alzheimer's.

Worldwide, around 50million people have dementia and the total number is projected to reach 82 million in 2030 and 152 in 2050, according to the World Health Organization.

Alzheimer's disease, the most common form of dementia, may contribute to 60-70 per cent of cases. Presently, there is no truly effective treatment for this disease.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 08 2018 | 11:15 AM IST

Next Story